The Braves were added to the list of teams showing interest in Casey Mize on August 1, giving Atlanta another name to watch as the trade market for starting pitching picks up. Jon Heyman of The New York Post reported the update, and Gabriel Burns of the Atlanta Journal-Constitution wrote that Mize looks likelier than Tarik Skubal to end up in Atlanta if Detroit deals from its rotation.
That is why the Braves Trade search is spiking now. Mize, 29, is in his final season of club control with Detroit and has pitched like a pitcher who could help quickly: 86 2/3 innings, a career-low 2.70 ERA, a career-high 24.9% strikeout rate and a 5.6% walk rate. He has earned $6.15MM this season and has about $1.85MM left to be paid out, which keeps him in the range of an affordable rotation add for a club looking to patch holes without paying top-of-the-market prices.
Detroit is not dealing from a position of comfort, either. Mize was placed on the 15-day injured list in late April with a right adductor strain, came back after the minimum stay and then returned to the injured list after inflammation in the same area flared up again. He spent another three weeks on the shelf, and the club scratched him from yesterday's start as interest in him picked up. That decision sits awkwardly beside what he told the Tigers beat: he said he feels healthy.
The numbers show why the interest is real and why the fit is obvious. Mize's four-seamer averaged 93.6 mph through his first 15 starts, then dipped to 91.9 mph against the Royals last Saturday, a small but telling reminder that clubs will be weighing both performance and durability. The Braves have been hunting for rotation answers all season, with Spencer Schwellenbach out for the year, Spencer Strider on the 60-day IL because of elbow inflammation, and Hurston Waldrep and AJ Smith-Shawver missing most of the season.
The next question is whether Detroit actually moves him before the deadline, because interest alone does not force a deal. Tarik Skubal remains the biggest prize if the Tigers choose to sell, but Mize has become the cleaner middle path: useful now, cheaper than a frontline arm and likely to draw more than one bidder. If Atlanta keeps pressing, the market may decide whether this Braves Trade talk turns into a real move or just another name on the board.
